Definition

An orally bioavailable radioconjugate composed of fluzoparib, an orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2, radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of fluzoparib. Upon administration of carbon C 14 fluzoparib, fluzoparib targets, binds to and inhibits PARP, which results in the inhibition of tumor cell proliferation and survival. Labeling of fluzoparib with the radioactive tracer carbon C 14 allows for the evaluation of fluzoparib’s pharmacokinetic profile, including its absorption, distribution, metabolism and excretion (ADME).